Navigation Links
Abeome Forms First Class Scientific Advisory Board
Date:9/10/2008

ATHENS, Ga., Sept. 10 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, today announced the formation of its Scientific Advisory Board (SAB) to collaborate on the development of Abeome's ovarian cancer project and to select and guide future therapeutic and diagnostic projects for the company.

The SAB will be led by scientific founder Richard Meagher, PhD, Chief Scientific Officer for Abeome, Distinguished Research Professor at the University of Georgia, and inventor of Abeome's patented monoclonal antibody technology. The SAB will consist of:

Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations as well as for her broad scientific applications of biotechnology, genomics and biomarker discovery in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases. Dr. Debouck brings 24 years of experience in directing creative science in diverse areas of research.

Jeff Boyd, PhD, Chief Scientific Officer and Sr. VP at Fox Chase Cancer Center in Philadelphia, has an international reputation as one of the leading scientists in the study of molecular genetics of women's cancers. Dr. Boyd was named Distinguished Cancer Scholar by the Georgia Cancer Coalition. His long-term research focus has studied molecular genetics of ovarian cancer with emphasis on hereditary predisposition.

Linda Matsuuchi, PhD, Associate Director of the Life Sciences Institute at the University of British Columbia, has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes, the source of antibody production.

"We are pleased to assemble such an incredibly talented team of scientists to serve on our SAB and to participate in target validation on our ovarian cancer therapeutic project. Their active participation provides Abeome with valuable expertise in pre-clinical and clinical trials, unparalleled knowledge of ovarian cancer pathology, and years of immunology experience specific to monoclonal antibody development," states Abeome CEO, Mike Wanner.

"The company will deploy its monoclonal antibody technology to rapidly develop a pipeline of therapeutic candidates in a number of cancer areas and will benefit by these individual's commitment to our mission. They join an already outstanding group of Abeome scientists, biotech-oriented Board of Directors, and scientific founder, Dr. Richard Meagher to form a team of world-class scientists to insure Abeome's future success."

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance. Its current focus is on developing a cancer therapeutic and diagnostic for ovarian cancer.

For more information on Abeome, visit http://www.abeomecorp.com.


'/>"/>
SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management
2. Neogen Forms Mexican Subsidiary
3. BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts
4. American Oriental Bioengineering Forms Science and Technology Advisory Committee
5. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
6. Agrenco Informs Sale of Biodiesel at ANP Auction
7. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
8. International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative
9. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
10. febit Forms Scientific Advisory Board
11. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its imprint in ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT EACH ... using capacitive technology represent a fast growing market, especially ... increase of 360% of the number of fingerprint sensor ... market between 2014 and 2017 (source : N+1 Singer, ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
Breaking Biology News(10 mins):